In a clinical trial of Wegovy, people lost an average of 14% of their body weight at 64 weeks alongside diet and exercise.
Posted by On with Kara Swisher, Checked
- Sources
- 8 support
- Said
- 1 time·
- Confidence
- 85%
On with Kara SwisherAug 10, 2026
The 14% average weight loss at 64 weeks is supported: the OASIS 4 trial of oral Wegovy 25 mg, run alongside diet and exercise, reported about 14% (13.6%) loss regardless of adherence, versus about 2% for placebo.
An ad makes this claim. It counts as passed on, not against the post.
What was said
… Wogovi is the first ever GLP-1 weight loss medication available in a pill, but also comes as a pen, so you've got options. With Wogovi, you can lose up to 20% of your body weight. People lost an average of 14% body weight at 64 weeks in a clinical trial of Wogovi alongside diet and exercise. To get started with Wogovi, just go to for hers dot com and complete an online consultation with a licensed provider, who will determine if your prescription is appropriate. And Hers doesn't stop there. …
On with Kara Swisher · · from the transcriptPost →What we found
Supports. Reuters reports that oral Wegovy led to about a 14% reduction in body weight over 64 weeks in separate studies.[1]
Supports. Novo Nordisk and Wegovy.com state that the 64-week OASIS 4 trial, with reduced-calorie diet and increased physical activity, produced average weight loss of about 14% (13.6%) with Wegovy pill versus about 2% with placebo.[2][3][4][5]
Supports. WebMD, Everyday Health and US News independently report the ~14% average loss at 64 weeks for the Wegovy pill, with the trial described as including lifestyle support.[6][7][8]
Context. The 14% figure is the all-patients (treatment-policy) estimate; the per-protocol figure for patients who stayed on treatment was about 17%. Both are reported, and the claim matches the lower, all-patients figure.[3][4][5]
Context. The post's spelling 'Wogovi' is treated as the Wegovy pill, which the same passage describes as the first GLP-1 weight-loss pill. This is a name-spelling resolution, not a different product or scope.
Sources
8 sources: 1 fact-checker, 7 not rated
- 1Many US patients opt for obesity drug injections, defying ...reuters.com · fact-checker · cited for: supports
- 2Wegovy® Pill Trial Findings for Weight Losswegovy.com · not rated · cited for: supports
- 3News Detailsnovonordisk.com · not rated · cited for: supports, context
- 4FDA Approves Oral Wegovy® Pill | Novo Nordisk U.S.novonordisk-us.com · not rated · cited for: supports, context
- 5Wegovy® pill (semaglutide tablets), the first daily oral GLP ...novonordisk.co.uk · not rated · cited for: supports, context
- 6First GLP-1 Pill for Weight Loss Gets FDA Approvaleverydayhealth.com · not rated · cited for: supports
- 7FDA Approves Once-Daily Wegovy Pill as the First Oral ...webmd.com · not rated · cited for: supports
- 8Wegovy Pill vs. Foundayo Pill: How the 2 New GLP-1 Drugs Comparehealth.usnews.com · not rated · cited for: supports
Where this claim was made
Said in 1 published post